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Abstract
Background: Analysis of an allelic series of point mutations in a gene, generated by N-ethyl-N-nitrosourea (ENU) mutagenesis,
is a valuable method for discovering the full scope of its biological function. Here we present an efficient gene-driven approach
for identifying ENU-induced point mutations in any gene in C57BL/6J mice. The advantage of such an approach is that it allows
one to select any gene of interest in the mouse genome and to go directly from DNA sequence to mutant mice.
Results: We produced the Cryopreserved Mutant Mouse Bank (CMMB), which is an archive of DNA, cDNA, tissues, and sperm
from 4,000 G1 male offspring of ENU-treated C57BL/6J males mated to untreated C57BL/6J females. Each mouse in the CMMB
carries a large number of random heterozygous point mutations throughout the genome. High-throughput Temperature
Gradient Capillary Electrophoresis (TGCE) was employed to perform a 32-Mbp sequence-driven screen for mutations in 38
PCR amplicons from 11 genes in DNA and/or cDNA from the CMMB mice. DNA sequence analysis of heteroduplex-forming
amplicons identified by TGCE revealed 22 mutations in 10 genes for an overall mutation frequency of 1 in 1.45 Mbp. All 22
mutations are single base pair substitutions, and nine of them (41%) result in nonconservative amino acid substitutions.
Intracytoplasmic sperm injection (ICSI) of cryopreserved spermatozoa into B6D2F1 or C57BL/6J ova was used to recover
mutant mice for nine of the mutations to date.
Conclusions: The inbred C57BL/6J CMMB, together with TGCE mutation screening and ICSI for the recovery of mutant mice,
represents a valuable gene-driven approach for the functional annotation of the mammalian genome and for the generation of
mouse models of human genetic diseases. The ability of ENU to induce mutations that cause various types of changes in proteins
will provide additional insights into the functions of mammalian proteins that may not be detectable by knockout mutations.
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Background
A major challenge following the sequencing of the human
genome is to determine the biological functions of the
estimated 30,000 genes. Inducing mutations in mouse
genes and determining their consequences in the whole
animal is a powerful approach for gaining insight into the
functions, regulatory networks, and gene-environment
interactions of homologous human genes. To provide a
systematic and comprehensive functional annotation of
every gene in the genome using mouse mutagenesis will
undoubtedly require numerous complementary strate-
gies, such as gene knockouts, conditional knockouts, and
point mutagenesis with the chemical N-ethyl-N-nitrosou-
rea (ENU) [1,2].
The ethylating chemical ENU is the most potent mutagen
in the mouse, with a per-locus mutation frequency, based
mainly on detecting mutant phenotypes at visibly marked
loci, ranging from approximately 1/1500 for a single 250
mg/kg dose to 1/700 for a fractionated 4 × 100 mg/kg
dose [3,4]. Since ENU induces primarily single base pair
(bp) substitutions in DNA, it is especially useful for pro-
ducing an allelic series of mutations in a gene, where each
mutation may result in different degrees of severity of the
mutant phenotype or even in completely different mutant
phenotypes. Depending on the location of the mutation
within the gene and on the specific base pair substitution,
ENU-induced mutations may cause amorphic (loss of
function), hypomorphic (partial loss of function), anti-
morphic (opposing/dominant negative function), hyper-
morphic (exaggerated function), and neomorphic (novel
gain of function) protein changes, which permit a fine-
scale dissection of gene function and generally reflect the
types of gene variations found in the human population.
This ability of ENU to induce mutations that cause various
types of changes in proteins provides valuable insights
into protein structure and function that cannot be
obtained with knockout mutations.
The power of ENU (and ethyl methanesulfonate) as a tool
for the high-throughput functional annotation of gene
sequences has been applied to two primary mutagenesis
strategies in mice using either whole mice or mouse
embryonic stem (ES) cells: the phenotype-driven muta-
genesis screen [5-22] and, more recently, the gene-driven
mutagenesis screen [22-30]. An advantage of the pheno-
type-driven approach is that it does not presuppose the
functional roles of any of the genes in the genome, per-
mitting the investigator to identify genes in specific bio-
logical processes, pathways, or responses based on the
phenotype screens being employed. The strategy yields
definitive mutant phenotypes, which cannot always be
predicted in gene-driven approaches. Furthermore, phe-
notype screens have often identified mutations in novel
genes, or in known genes for which the resulting mutant
phenotypes were not readily predictable from the bio-
chemical functions of the gene products. However, after
identifying mice with the desired mutant phenotype, the
underlying genetic mutation must still be mapped and
cloned. Additionally, phenotype-driven mutagenesis is
not a viable approach for recovering mutations in a pre-
selected set of genes for which no functional information
is available.
The completion of the mouse genome sequence and the
development of new efficient methods for the rapid detec-
tion of single-nucleotide polymorphisms (SNPs) have
made it practical to functionally annotate mammalian
genes using high-throughput, cost-effective, gene-driven
mutagenesis strategies in the mouse. The benefit of a gene-
driven mutagenesis approach is that one can go directly
from the DNA sequence information for any gene to the
isolation of mutations. Gene-driven mutagenesis screens
have been performed both in mouse ES cells [23,26] and
in the whole mouse [25,27,29,30]. In practice, the DNAs
from large numbers of mutagenized ES-cell clones or the
G1 progeny of mutagenized male mice are screened for
mutations in pre-selected target genes by high-throughput
SNP detection methods, and the cryopreserved ES cells or
sperm are used to recover mutant mice for phenotype
analysis.
These recent developments in ES cells and in mice demon-
strate that it is now possible to take full advantage of the
availability of the mouse genome sequence and the muta-
genicity of ENU to rapidly produce allelic series of muta-
tions in target genes for functional genomics studies. To
complement existing embryonic stem-cell-based gene-
driven mutagenesis resources, such as gene-trap libraries
[31] and ENU-mutagenized CT129/Sv ES cells [23], as
well as ENU-mutagenized mice on a mixed genetic back-
ground [27,30] or a C3HeB/FeJ inbred genetic back-
ground [29], we generated a cryopreserved bank in the
C57BL/6J inbred genetic background consisting of DNA,
eight pooled organs (for RNA and protein), and sperm
from 4,000 G1 mice that each carry a load of paternally
induced ENU mutations. This Cryopreserved Mutant
Mouse Bank (CMMB) is a source of induced, heritable
SNPs in virtually every gene in the genome. We used high-
throughput Temperature Gradient Capillary Electro-
phoresis (TGCE) [32] to screen a total of 32 Mbp of PCR-
amplified DNA and cDNA from these CMMB mice, which
resulted in the identification of 22 ENU-induced muta-
tions in 10 target genes. Because of the advantage of keep-
ing the CMMB on the sequenced C57BL/6J background
for future widespread ease of use of the mutant mice, and
the inherent difficulties in recovering C57BL/6J mice from
cryopreserved sperm by in vitro fertilization (IVF), we
applied intracytoplasmic sperm injection (ICSI) of cryop-
reserved sperm for the recovery of mutations.BMC Genomics 2005, 6:164 http://www.biomedcentral.com/1471-2164/6/164
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The unique features of the gene-driven mutagenesis
approach presented here include: (1) the CMMB was gen-
erated on the defined C57BL/6J genetic background; (2)
in addition to genomic DNA, cDNA templates isolated
from the pooled, cryopreserved organs of each mouse
were also screened for mutations; (3) single-pass, multi-
plexed TGCE was implemented for high-throughput
mutation screening; and (4) live mutant mice were suc-
cessfully recovered from the cryopreserved sperm by ICSI,
an assisted reproduction technique that will significantly
extend the life of the sperm for each of the 4,000 males in
the CMMB and that will provide for gene-specific point
mutations recovered on an inbred C57BL/6J background.
Thus, the CMMB will be a useful resource for providing
mouse models with a wide range of altered proteins for
phenotypic, gene/protein-network, and structural biol-
ogy-type analyses.
Results
Construction of the CMMB
The CMMB consists of genomic DNA, cDNA, tissue pow-
ders, and sperm harvested from 4,000 G1 male mice born
from the mating of ENU-treated C57BL/6J males to
untreated C57BL/6J females. At the time of euthanasia,
genomic DNA was prepared from the tail of all 4,000 mice
and the sperm was cryopreserved. Additionally, eight
organs (brain, heart, spleen, lungs, kidneys, testes, and
portions of the liver and small intestine) were harvested,
snap frozen in liquid nitrogen, pooled, ground into a
powder, and stored in liquid nitrogen. To date, one-fourth
of the pooled tissue powder from each of the first 736
mice (~18% of the CMMB) was used to prepare RNA and
first-strand cDNA for mutation screening. The 4,000
DNAs and 736 cDNAs were arrayed into 96-well plates for
PCR amplification of selected genes and mutation screen-
ing by TGCE (Fig. 1).
Gene-driven ENU-induced mutagenesis of any mouse gene using the Cryopreserved Mutant Mouse Bank (CMMB) Figure 1
Gene-driven ENU-induced mutagenesis of any mouse gene using the Cryopreserved Mutant Mouse Bank 
(CMMB). Flowchart showing: generation of the CMMB, PCR amplification of selected genes from the DNA and cDNA tem-
plates, mutation screening of PCR products by TGCE and DNA sequencing, and recovery of mutant mice from cryopreserved 
sperm by ICSI (see text for details).
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Screening the CMMB for ENU-induced point mutations by 
TGCE
Screening of the CMMB for gene-specific point mutations
followed the protocol outlined in Figure 1. Specific seg-
ments of selected genes were amplified by PCR from the
genomic DNA or cDNA templates in the CMMB. The PCR
products were denatured and reannealed to generate het-
eroduplexes in those samples where an ENU-induced
point mutation was present. High-throughput TGCE anal-
ysis was then employed to screen the PCR products for the
presence of heteroduplexes. TGCE analysis was performed
in a 96-capillary array instrument (SpectruMedix
SCE9612), in which PCR-amplified DNA and cDNA sam-
ples were separated by capillary electrophoresis in a single
broad temperature gradient. Samples containing muta-
tions were identified on the basis of altered electro-
phoretic patterns of homoduplexes and heteroduplexes
caused by their different melting equilibria and electro-
Identification of a mutation in the CMMB by multiplexed RT-PCR and TGCE, followed by DNA sequencing to identify the spe- cific base pair substitution Figure 2
Identification of a mutation in the CMMB by multiplexed RT-PCR and TGCE, followed by DNA sequencing to 
identify the specific base pair substitution. (A) Agarose gel electrophoresis of multiplexed RT-PCR reactions. Shown are 
four representative samples from each of two independent three-fold multiplexed PCR reactions (multiplex 7 and 10) of 
cDNA templates in the CMMB. Sizes (bp) of molecular weight markers are shown on the left. Sizes (bp) of RT-PCR products 
of the multiplex 10 reaction are shown on the right. The asterisk indicates the product (510 bp) in which a mutation was iden-
tified by TGCE in panel B. (B) TGCE electropherogram profiles of three-fold multiplexed PCR products (multiplex 10) derived 
from CMMB mouse #131 (top) and C57BL/6J control (bottom) cDNA templates. A mutation (heteroduplex, red arrow) was 
identified in CMMB #131 in a 510-bp product derived from the Ap2a1 gene. (C) The mutation was confirmed by repeating the 
RT-PCR and TGCE analysis of only the 510-bp product amplified from the CMMB #131 cDNA sample. (D) DNA sequence 
analysis of the 510-bp products amplified from the CMMB #131 and control cDNAs revealed an A-to-G nucleotide substitu-
tion (red arrow) in the Ap2a1 gene in the CMMB #131 sample, which causes a Glu414Gly amino acid substitution in the 
encoded protein.
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Table 1: Mutations identified in the CMMB. Types of ENU-induced gene mutations identified by TGCE screening of DNA and cDNA templates from 4,000 C57BL/6J mice in the 
CMMB, and recovery of mutant lines from the cryopreserved sperm by ICSI.
Gene 
symbola
Amplicon 
size (bp)
Template 
(D-DNA C-cDNA)
Number of 
individuals 
screenedb
Mbp 
screened
Mutations 
identified, 
(mouse #)c
GenBank 
accession 
number
Base 
mutationd
Amino acid 
change
Type of mutation Rederived 
by ICSI
Mc1r 579 D 1585* 0.917 0 NM_008559
Mc1r 446 D 1667* 0.743 1 (1110) NM_008559 T781C Phe256Ser Nonconservative Yes
Mc1r 527 D 1671* 0.880 1 (997) AF176016 A115G Promoter Promotere Yes
Zfp111 352 D 1686* 0.593 0 NM_019940
Zfp111 327 D 1250* 0.409 1 (803) NM_019940 G2182A 3' UTR 3' UTRf Yes
Scnm1 394 D 3641 1.434 0 NM_027013
Scnm1 484 D 3400 1.645 1 (1128)
1 (3789)
NM_027013
AC140190
T428C
T19199C
Ile112Thr 
Intronic
Nonconservative 
Intron 5g
Yes
Scnm1 372 D 3800 1.414 1 (2364) NM_027013 A594G Ser167Ser Silent
Usp29 300 D 3884 1.165 1 (3909) NM_021323 G1850A Glu124Lys Nonconservative Yes
Usp29 336 D 3544 1.191 1 (1954) NM_021323 T2933A Cys485Ser Conservative
Usp29 298 D 3621 1.079 1 (573) NM_021323 A3516G Lys679Arg Conservative
Zim1 298 D 2037* 0.607 1 (195) NM_011769 A808G Lys176Arg Conservative
Zim1 298 D 3720 1.109 1 (2277) NM_011769 A1017G Lys246Glu Nonconservative
Zim1 302 D 3726 1.125 1 (1027)
1 (3119)
NM_011769
NM 011769
T1660A
A1610G
Val460Glu
Gly443Gly
Nonconservative
Silent
Zim1 302 D 3801 1.148 0 NM_011769
Myd88 429 D 3725 1.598 0 NM_010851
Myd88 196 D 3669 0.719 0 NM_010851
Myd88 497 D 3739 1.858 1 (364) NM_010851 G604A Val175Met Conservative
Myd88 245 D 3836 0.940 1 (1569) NM_010851 T899A Ile273Lys Nonconservative Yes
Ap2s1 424 D 3754 1.592 0 NM_198613
Capsl 372 D 3694 1.374 1 (661) NT_039618 T418425A Intronic Intron 2h
Capsl 344 D 2422* 0.833 1 (1813) NM_029341 G665A Leu125Leu SilentB
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Antxr1 419 D 3726 1.560 1 (832) AC153853 A188590G Intronic Intron 1i
Antxr1 335 D 3739 1.253 1 (1176) AC153853 T94846A Intronic Intron 4j
Antxr1 157 D 3841 0.603 0 NM_054041
Antxr1 363 C 714* 0.259 0 NM_054041
Antxr1 490 C 728* 0.357 0 NM_054041
Antxr1 489 C 718* 0.351 0 NM_054041
Ap2a1 510 C 713* 0.364 1 (131) NM_007458 A1446G Glu414Gly Nonconservative Yes
Ap2a1 543 C 732* 0.397 1 (663) NM_007458 T796A Asn197Lys Nonconservative Yes
Ap2a1 442 C 729* 0.322 0 NM_007458
Ap2a1 531 C 730* 0.388 0 NM_007458
Ap2a1 351 C 707* 0.248 0 NM_007458
Pak4 503 C 441* 0.222 1 (61) NM_027470 C1094T Pro283Ser Nonconservative Yes
Pak4 477 C 728* 0.347 0 NM_027470
Pak4 459 C 707* 0.325 0 NM_027470
Pak4 412 C 728* 0.300 0 NM_027470
Pak4 447 C 731* 0.327 0 NM_027470
TOTAL 31.996 22
aMc1r, melanocortin 1 receptor; Zfp111, zinc finger protein 111; Scnm1, sodium channel modifier 1; Usp29, ubiquitin specific protease 29; Zim 1, zinc finger, imprinted 1; Myd88, myeloid 
differentiation primary response gene 88; Ap2s1, adaptor-related protein complex 2, sigma 1 subunit; Capsl, calcyphosine-like; Antxr1, anthrax toxin receptor 1; Ap2a1, adaptor protein complex 
AP-2, alpha 1 subunit; Pak4, p21 (CDKN1A)-activated kinase 4
bAsterisk indicates that only a portion of the CMMB was screened for the amplicon
cNumber in parentheses indicates the CMMB animal number in which the mutation was identified
dBases are numbered according to corresponding GenBank accession number and refer to the sense strand
e-681 bp upstream of start codon
f+7 bp downstream of stop codon
gintron 5, +62 bp downstream of end of exon 5
hintron 2, -7 bp upstream of start of exon 3
iintron 1, -33 bp upstream of start of exon 2
jintron 4, +75 bp downstream of end of exon 4
Table 1: Mutations identified in the CMMB. Types of ENU-induced gene mutations identified by TGCE screening of DNA and cDNA templates from 4,000 C57BL/6J mice in the 
CMMB, and recovery of mutant lines from the cryopreserved sperm by ICSI. (Continued)BMC Genomics 2005, 6:164 http://www.biomedcentral.com/1471-2164/6/164
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phoretic mobilities [32]. Samples containing heterodu-
plexes were confirmed by repeating the TGCE analysis
only on those samples, and then sequenced to identify the
specific base pair mutation.
Prior to the large-scale PCR and TGCE screening of the
CMMB for mutations in selected gene fragments (ampli-
cons), the following PCR, TGCE, and DNA sequencing
quality-control measures were implemented. PCR primers
were designed to amplify genomic DNA containing one or
two larger exons and the adjacent splice sites, or to
amplify cDNA spanning multiple smaller exons. The
amplicons were designed to be ~150–600 bp in length.
The optimal annealing temperature of the primers in each
PCR or RT-PCR reaction was determined using a gradient
thermal cycler, and the products were examined by elec-
trophoresis through agarose gels and by TGCE to evaluate
their suitability for mutation screening. The PCR ampli-
cons were also purified and sequenced on both strands
with the same primers used to generate the PCR product,
in order to confirm the specificity of the PCR reactions.
High-throughput mutation screening of the CMMB was
performed by PCR amplification of the DNA and cDNA
samples in 96-well plates, followed by the direct analysis
of these PCR products for mutations (heteroduplexes) by
TGCE. Amplicons were initially analyzed by TGCE in two
overlapping temperature gradients (50–58°C and 55–
63°C). Subsequent improvements in the gel matrix used
for TGCE in the SCE9612 instrument permitted the anal-
ysis of all amplicons in a single 50–60°C temperature gra-
dient. Sixteen of the 22 mutations reported here were
identified using this new high-viscosity high-resolution
gel matrix. Our maximum throughput for TGCE analysis
using the new matrix in the SCE9612 was nine 96-well
plates per day. The 4,000 DNA samples are in forty-four
96-well plates (92 CMMB samples and 4 control samples
per plate). Thus, one amplicon can be screened in the
entire CMMB in one week.
We increased the throughput of mutation detection an
additional three-fold by routinely performing PCR ampli-
fication and TGCE analysis of multiple amplicons simul-
taneously (i.e., multiplexing). A typical three-fold
multiplex experiment with cDNA templates is shown in
Figure 2. Three pairs of PCR primers were combined in a
single PCR reaction for each of the CMMB cDNA tem-
plates (Fig. 2A). The PCR products were then directly ana-
lyzed for the presence of heteroduplexes by TGCE, which
resulted in the identification of a mutation in one of the
three multiplexed amplicons in CMMB sample #131 (Fig.
2B). This mutation was confirmed by repeating the PCR
and TGCE analysis of sample #131 (Fig. 2C), and direct
DNA sequence analysis of the PCR product identified an
ENU-induced A-to-G mutation in the heterozygous DNA
sample (Fig. 2D). We also determined that the throughput
for mutation detection can be increased an additional 10-
fold by pooling the DNA or cDNA templates (placing
templates from 10 mice in each well) prior to PCR and
TGCE analysis [[32]; and data not shown].
Mutation screening by TGCE with a single broad range of
temperatures eliminates the need to determine the opti-
mum melting temperature for any amplicon, and also
increases the efficiency and throughput of the screen. As a
result of this broad temperature range, the four peaks that
are expected in an electropherogram following TGCE
analysis of a DNA sample with a heterozygous point
mutation (both heteroduplexes, and wild-type and
mutant homoduplexes) are, in practice, typically com-
pressed into two peaks. Of the 22 mutations reported here
(Table 1), two were detected as three peaks, 16 were
detected as two peaks, and the remaining four mutations
were seen as "shoulders" on the primary peak, all follow-
ing first-pass TGCE analysis (Fig. 3).
Types of mutations and mutation frequency in the CMMB
Genomic DNA and cDNA templates were used to screen
for mutations in 38 amplicons from 11 genes by TGCE
analysis (Table 1). The entire CMMB (DNA) was screened
for 18 of these amplicons, whereas a portion of the bank
(DNA or cDNA) was screened for the remaining 20 ampli-
cons, resulting in a total 32.0-Mbp screen. Amplicon sizes
ranged from 157 to 579 bp. A total of 22 point mutations
was identified in 10 of the 11 genes, which equals a muta-
tion frequency of 1 mutation for every 1.454 Mbp
screened. Thus, on average, screening a 364-bp amplicon
in all 4,000 samples in the CMMB will yield one new
mutation. The number of mutations identified per ampli-
con ranged from none to two. Of the 22 mutations iden-
tified: (a) 19 were identified in genomic DNA templates
and the remaining three in cDNA templates; (b) 17
occurred in A-T base pairs and five in G-C base pairs; (c)
16 were transitions and six were transversions; and (d) 16
occurred in the coding regions of genes, one was in the
promoter, one was in the 3' UTR, and four were in introns.
Of the 16 mutations that occurred in the coding regions of
genes, 13 were missense mutations (nine nonconservative
and four conservative amino acid substitutions) and three
were silent mutations.
Two sequence homology-based tools, Sorting Intolerant
From Tolerant (SIFT) [33] and Polymorphism Phenotyp-
ing (PolyPhen) [34], were used to predict the potential
impact of the 13 nonsynonymous DNA changes on pro-
tein structure and function (Table 2). Generally speaking,
these programs predict whether an amino acid substitu-
tion will impact protein function based on sequence com-
parisons among evolutionarily related proteins. The
potential impact of each nonsynonymous change isBMC Genomics 2005, 6:164 http://www.biomedcentral.com/1471-2164/6/164
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Four categories of electropherogram profiles generated by high-throughput TGCE mutation screening of DNA and cDNA  samples in the CMMB Figure 3
Four categories of electropherogram profiles generated by high-throughput TGCE mutation screening of 
DNA and cDNA samples in the CMMB. The 22 ENU-induced mutations identified in this study (see Table 1) by TGCE 
analysis of heteroduplexed PCR products produced electropherogram patterns that can be divided into four general categories 
based on the number and shape of the peaks. Shown are representative electropherograms from each category, which include: 
(A) three peaks (CMMB #1128, 484-bp amplicon, Scnm1); (B) two peaks of approximately equal intensity (CMMB #3789, 484-
bp amplicon, Scnm1); (C) two peaks with lower intensity of the heteroduplex peak (CMMB #1954, 336-bp amplicon, Usp29): 
and (D) a shoulder on the main peak (CMMB #1176, 335-bp amplicon, Antxr1). In each of the four panels the electrophero-
gram on the top is from the indicated CMMB sample with a heterozygous ENU mutation and the electropherogram on the 
bottom is from an untreated C57BL/6J control sample. All patterns shown were obtained from first-pass TGCE screening of 
unpurified PCR products using a single 50–60°C gradient. Heteroduplex molecules (arrows) denature faster than the homodu-
plexes as temperature increases during electrophoresis. The distribution of electropherogram patterns observed for the 22 
mutations can be categorized as follows: (A) 2, (B) 4, (C) 12, and (D) 4 mutations. Thus, 82% of the profiles exhibited two or 
more peaks and the remaining 18% were shoulders.
AB
C D
C57BL/6J
CMMB #3789
CMMB #1176
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reported as tolerated or not tolerated (SIFT), or benign,
possibly damaging, or probably damaging (PolyPhen).
Recovery of mutant mice from cryopreserved sperm by 
ICSI
The CMMB includes 10 straws of sperm from each mouse.
Upon thawing one straw for ICSI, the sperm was washed
with NIM medium (see Methods) to remove the cryopro-
tectant, resuspended in NIM medium, aliquoted into 20
cryovials, refrozen, and stored in liquid nitrogen. One of
these 20 smaller aliquots of sperm was used per morning
of ICSI, thus providing for ~200 days of ICSI for each G1
male in the CMMB.
As an additional quality-control measure prior to the
recovery of mutant mice with the cryopreserved sperm,
the mutation of interest was re-sequenced in the sperm
DNA. ICSI was performed essentially as described [35]
with minor modifications (see Methods). To date, live
mutant mice have been recovered for nine of the 22 muta-
tions by injecting the cryopreserved C57BL/6J sperm into
B6D2F1 ova (Table 1). Most of our injections have been
performed with B6D2F1 ova because of the increased effi-
ciency of recovering live mice from cryopreserved C57BL/
6J sperm using hybrid ova [36]. However, ICSI was also
performed with C57BL/6J ova for one of these nine muta-
tions and live mice were recovered, demonstrating the
ability to recover CMMB mice on the C57BL/6J genetic
background. Future efforts will be directed toward recov-
ering mutant CMMB mice with only C57BL/6J ova.
Genotyping and breeding mutant mice for phenotype 
analysis
G2 mice recovered by ICSI with C57BL/6J G1 sperm and
B6D2F1 ova were genotyped for the presence of the heter-
ozygous point mutation with the same PCR and TGCE
methods used to identify the mutation originally in the
CMMB. Heterozygous G2 mutant mice were then mated to
wild-type C57BL/6J mice to produce heterozygous G3 off-
spring. Multiple pairs of heterozygous G3 mice were inter-
crossed to produce 20 G4 mice for phenotype analysis.
Offspring from the G3 intercrosses were genotyped by
TGCE or DNA sequencing of PCR products (see Meth-
ods).
The nine lines of mutant mice recovered by ICSI are at var-
ious stages in this process, ranging from heterozygous G2
mice, to homozygous mutant G4 animals that are under-
going phenotype analysis. The results of the phenotype
analyses will be described elsewhere. We are also in the
process of cryopreserving embryos for the lines of mutant
mice recovered by ICSI. The frozen embryos will then be
advertised on our web site at ORNL [37], which can also
be searched via the International Mouse Strain Resource
web site [38].
Discussion
In this study we generated a bank of DNA, tissues, and
sperm from 4,000 male progeny of ENU-mutagenized
C57BL/6J mice, employed TGCE as a high-throughput
and cost-effective gene-driven approach for identifying
mutations, and used ICSI to recover live mice from cryop-
reserved sperm of males carrying specific mutations. An
initial 32.0-Mbp screen of genomic DNA and cDNA tem-
plates in the CMMB resulted in the identification of 22
point mutations, with a per-base-pair mutation frequency
of 1 in 1.454 Mbp (Table 1). This mutation frequency is
comparable to the frequency reported for other gene-
driven ENU mutagenesis screens in mice [27,29,30]. Of
these 22 mutations, 13 of them (59%) were missense
Table 2: SIFT and PolyPhen predictions of the possible impact of 13 amino acid variants in the CMMB on protein structure and 
function.
Gene (protein ID) Amino acid change SIFT scorea SIFT prediction PolyPhen prediction
Mc1r (NP_032585) Phe256Ser (0.00) (Not Tolerated) Possibly Damaging
Scnm1 (NP_081289) Ile112Thr (0.44) (Tolerated) Benign
Usp29 (NP_067298) Glu124Lys (0.05) (Tolerated) Benign
Usp29 (NP_067298) Cys485Ser 0.01 Not Tolerated Probably Damaging
Usp29 (NP_067298) Lys679Arg 0.05 Tolerated Benign
Zim1 (NP_035899) Lys176Arg 0.62 Tolerated Benign
Zim1 (NP_035899) Lys246Glu (0.30) (Tolerated) Benign
Zim1 (NP_035899) Val460Glu 0.18 Tolerated Benign
Myd88 (NP_034981) Val175Met 0.01 Not Tolerated Benign
Myd88 (NP_034981) Ile273Lys 0.29 Tolerated Probably Damaging
Ap2a1 (NP_031484) Glu414Gly 0.23 Tolerated Possibly Damaging
Ap2a1 (NP_031484) Asn197Lys 0.36 Tolerated Possibly Damaging
Pak4 (NP_081746) Pro283Ser 0.42 Tolerated Possibly Damaging
aSIFT scores indicate if amino acid changes are predicted to be Not Tolerated (<0.05) or Tolerated (≥0.05). SIFT scores and predictions in 
parentheses should be interpreted with caution because the median sequence conservation score was >3.25.BMC Genomics 2005, 6:164 http://www.biomedcentral.com/1471-2164/6/164
Page 10 of 18
(page number not for citation purposes)
mutations (nine nonconservative and four conservative)
with the potential to cause functional changes in the
encoded proteins. Therefore, one missense mutation was
identified in the CMMB per 2.46 Mbp screened, or one
potential functional change for every 615 bp screened in
all 4,000 mice. If we impose a stricter definition and con-
sider that only the nonconservative amino acid substitu-
tions are likely to cause functional protein changes, then
nine of the 22 mutations (41%) reported here are in this
category. Using this stricter definition, one functional
change was identified in the CMMB for each 3.56 Mbp
screened or, on average, one functional change (noncon-
servative amino acid substitution) was identified for every
890 bp screened in all 4,000 mice. Based on these data
and the current size of the Oak Ridge CMMB, screening an
entire gene with an open reading frame of ≥ 2.7 kb would
result in ≥ 3 functional alleles. To identify functional
allelic series' in smaller genes, or in a small discrete region
of a gene, it would be advantageous to proportionately
expand the size of the CMMB (e.g., a bank of 10,000 mice
would yield one functional change for any 356-bp ampli-
con).
The SIFT and PolyPhen programs predicted that seven of
the 13 nonsynonymous DNA changes might have an
effect on protein structure and function. The predictions
made by these tools were often in disagreement and
should therefore be viewed with caution. However, these
types of predictions do offer additional information when
trying to prioritize the order in which lines of mutant mice
will be recovered from frozen sperm for phenotype analy-
sis.
TGCE as a high-throughput screening method
TGCE [32] was employed as a rapid, efficient, and cost-
effective method for identifying ENU-induced point
mutations in the CMMB. The relatively new TGCE tech-
nology has been used for clinical applications to identify
mutations in Factor V [39], hepatitis C virus [40], mtDNA
in nonmelanoma skin cancer samples [41], and the cyctic
fibrosis transmembrane conductance regulator gene [42].
More recently, as part of a phenotype-driven ENU muta-
genesis screen, our group demonstrated that TGCE is an
effective method for identifying mutations in candidate
genes associated with mutant mouse phenotypes that
map to defined chromosome intervals [21], and two other
groups have applied TGCE to gene-driven ENU mutagen-
esis screens [29,30].
In the present study, we also demonstrated that TGCE is a
powerful tool for identifying rare mutations in pre-
selected genes within a large bank of mutagenized DNA
samples. There are numerous advantages to using TGCE
for gene-driven ENU-induced mutagenesis screens. TGCE
analysis has a greater than 95% mutation-detection rate
[39,41,42]. TGCE permits direct analysis of very small vol-
umes of unpurified PCR products that can also be multi-
plexed, even amplicons with different melting
temperatures. Mutations are identified from first-pass
screening without the need to predetermine the melting
temperatures of different amplicons. Finally, TGCE is sen-
sitive enough to permit sample pooling. In our hands
using the SCE9612, we were able to analyze nine 96-well
plates per day. We demonstrated a routine ability to per-
form three-fold multiplexing of samples, and we deter-
mined that we could identify single ENU mutations from
pools of 10 DNA samples. Experiments are under way to
combine PCR/TGCE multiplexing and sample pooling to
significantly increase throughput. For example, by pool-
ing eight samples (the columns in each 96-well plate), the
4,000 CMMB samples could be reduced to six 96-well
plates. If three amplicons (300, 400, and 500 bp) were
screened by PCR and TGCE simultaneously (three-fold
multiplex, see Fig. 2) in these pools of eight DNA samples,
a 4.8-Mbp screen could be completed in a single day. At
our current mutation frequency of 1 in 1.454 Mbp in the
CMMB, this could result in the identification of three
ENU-induced mutations per day, with at least one of them
causing a nonconservative amino acid change in the
encoded protein.
Screening both genomic DNA and cDNA templates
In addition to the 4,000 tail-DNA samples in the CMMB,
we began preparing and screening cDNA samples from
the corresponding 4,000 tissue powders. There are advan-
tages to having both DNA and cDNA for mutation screen-
ing. The DNA templates are more abundant and less
expensive to produce than cDNA templates, and they per-
mit the screening of exons and their splice junctions. Since
it is desirable in terms of throughput to screen large
amplicons that contain mostly coding sequences, DNA
templates are best suited for screening large single exons,
or two to three small exons separated by small introns.
However, because the average exon size in mouse is only
~250 bp (National Center for Biotechnology Informa-
tion), using cDNA templates allows one to design large
amplicons that consist only of coding sequences. Muta-
tion screening of cDNAs permits rapid coverage of the
gene's entire coding region, which is especially useful if
one wants to screen a conserved functional motif(s) that
spans numerous small exons spread across a large
genomic distance. One potential drawback to the use of
cDNA templates is that nonsense-mediated mRNA decay
could potentially decrease the efficiency of identifying
ENU-induced mutations that introduce premature termi-
nation codons, although this type of mutation will occur
infrequently compared to those that cause amino acid
substitutions. The possible decreased efficiency of identi-
fying such truncation mutations in our screen, which mayBMC Genomics 2005, 6:164 http://www.biomedcentral.com/1471-2164/6/164
Page 11 of 18
(page number not for citation purposes)
result in null alleles, would be minimized if a knockout
mutation already existed for the gene of interest.
Rationale for overcoming inbred C57BL/6J fertility 
problems by ICSI
The CMMB was deliberately generated with inbred
C57BL/6J mice so it would be in the "reference" genetic
background for the mouse genome. Although recovering
live mice from cryopreserved C57BL/6J sperm by IVF is
very inefficient compared to some other mouse strains
[43], this problem is overcome with ICSI [36,44,45]. We
used ICSI successfully to recover live mice from the cryop-
reserved CMMB sperm, including frozen sperm that was
thawed and refrozen without cryoprotectant, using both
B6D2F1 ova and C57BL/6J ova. Some lines were recov-
ered with only one or two sessions of ICSI injections.
Other lines required many attempts, but we have not yet
failed to recover any line. Although ICSI requires a higher
level of technical expertise and more hands-on time com-
pared to IVF, it is useful for recovering live mice from
highly mutagenized, frozen, C57BL/6J sperm, and it sig-
nificantly extends the life of the sperm bank. This latter
point is not a trivial issue, given that each of the 4,000
sperm samples in the bank came from a single G1 male.
Using ICSI to recover live mice from frozen sperm in the
CMMB, we effectively have enough sperm from one
CMMB male to perform a minimum of 200 days of ICSI.
More importantly, the extra effort involved in mutation
recovery with ICSI will be well worth it for the long-term
usefulness of the C57BL/6J mutant mice, especially since
most other mutations in the mouse genetic resource are
also on this background. Thus, in future tests of pheno-
typic effects of different CMMB alleles within an allelic
series, or when multiple mutations from the CMMB are
combined with each other or with mutations from differ-
ent sources into one line of mice to examine genetic inter-
actions, we expect background effects to be minimal.
"Off-target" mutations
An important consideration in any type of random muta-
genesis screen is the impact that mutation load and "off-
target" mutations will have on the ability to determine
that a specific mutation of interest is solely responsible for
the observed mutant phenotype. For this reason, we
elected to treat C57BL/6J mice with a fractionated dose of
ENU (3 × 85 mg/kg) that is less than the dose that can be
tolerated by this strain of mice [46]. The objective was to
obtain a mutation load that was high enough to make
screening efficient, but not so high that off-target muta-
tions became a significant concern. Assuming that all mis-
sense mutations we identified have the potential to
produce a functional protein change, our estimate of func-
tional mutation frequency in the Oak Ridge CMMB is 1 in
2.46 Mbp. Also assuming a 1,600-centimorgan 2.7-Giga-
base-pair haploid mouse genome of which 3% is coding,
each G1 male will have approximately 33 functional het-
erozygous mutations, with an average genetic distance
between mutations of 48 centimorgans, or an average of 2
mutations per autosome. Therefore, we can assume that
nearly all of these mutations will segregate independently,
and the likelihood of having tightly linked, off-target func-
tional mutations that confound phenotype interpretation
will be rare. Even so, it is expected that G2 mice will inherit
half of the mutations (17) from the G1 sperm, and that G3
mice will inherit half of these (9) from the G2 mice upon
backcross to untreated C57BL/6J mice. Only 25% of these
9 mutations (2) are expected to be present in both mice of
a G3 intercross breeding pair. Therefore, when G3 mice are
intercrossed to produce 20 G4 mice for phenotype analy-
sis, it is possible that 1 or 2 off-target mutations could
become homozygous in a portion of these mice. How-
ever, a false association of the mutant phenotype with the
target gene due to the co-segregation of an off-target muta-
tion is extremely unlikely. Such a false association would
require that homozygosity for the off-target mutation be
completely concordant with homozygosity for the target
mutation. Additionally, phenotype-genotype associations
will be confirmed in offspring from multiple pairs of G3
mice, effectively eliminating the chance of an occurrence
of co-homozygosity for an off-target mutation in all G4
target-mutation homozygotes. Finally, and importantly,
effects of off-target mutations can be ruled out by per-
forming phenotype analysis in compound heterozygous
mice in which the TGCE-detected ENU allele is in trans
with a null mutation generated by homologous recombi-
nation in ES cells.
Conclusions
The gene-driven mutagenesis approach presented here
offers significant advantages in performing time- and cost-
effective mutagenesis in mice, in screening for mutations
in target genes, and in re-deriving mutant mice. Only a
single generation of mice was needed to make the CMMB,
large numbers of G1 mice were generated and euthanized
in a short time, and the cost of making the bank was a
one-time investment. The design of the CMMB ensures
that none of the mutations to be recovered from the bank
are dominant lethals, since all of the heterozygous muta-
tions were present in the G1 individuals used to make the
bank. Using the CMMB for mutation screening offers the
advantage of screening for mutations in any target gene in
the genome (except those on the X chromosome) using
both DNA and cDNA templates, and recovering only
those lines of mice with pre-selected mutations from the
frozen sperm bank. The genes screened here were selected
on the basis of their importance in different biological
processes, but gene-driven ENU-based mutagenesis will
be especially useful for systems biology-based interroga-
tions of distinct genetic pathways and networks. The pri-
mary advantages of TGCE for mutation screening overBMC Genomics 2005, 6:164 http://www.biomedcentral.com/1471-2164/6/164
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other SNP detection methods, such as denaturing high-
performance liquid chromatography, lie in its ability to
detect mutations in unpurified, multiplexed PCR ampli-
cons with different denaturation temperatures, without
the need to predetermine the denaturation temperature
for any amplicon. Performing ICSI with frozen sperm
from the G1  mice in the CMMB provides numerous
opportunities to recover live mutant mice from multiple
different mutations that may occur in the same cryopre-
served sperm sample, and also allowed us to make the
entire bank on the widely used C57BL/6J reference genetic
background. In the future, mutations in different genes
may be crossed into one line of mice to better define pro-
tein-protein interactions in protein complexes, to observe
effects of mutations in certain "sensitized" backgrounds,
and to model multi-gene disease syndromes in humans
without the effects of modifying genes introduced by dif-
ferent genetic backgrounds. Thus, the generation of allelic
series' of point mutations by gene-driven ENU-induced
mutagenesis in mice provides an important complement
to knockout and conditional alleles in our quest to deter-
mine the whole-animal biological functions of all mam-
malian genes.
Methods
ENU mutagenesis
Seven groups of C57BL/6JRn male mice ≥ eight weeks old
(a total of 425 males) were each given three weekly intra-
peritoneal (IP) injections of 85 mg/kg ENU (Sigma-
Aldrich, St. Louis, MO) for a total fractionated dose of 255
mg/kg, as described [5]. Males were routinely bred to
untreated C57BL/6JRn females. Of the 425 injected
males, 319 males each produced an average of 13 G1
males (range of 1 to 43), for a total of 4,000 G1 males that
comprise the CMMB. C57BL/6JRn mice are C57BL/6J
mice purchased from The Jackson Laboratory in 1986 and
maintained continuously at the Oak Ridge National Lab-
oratory as an inbred stock; Rn = Rinchik. All use of mice
in this study was conducted under approved Institutional
Animal Care and Use Committee protocols and in accord-
ance with the Guide for the Care and Use of Laboratory Ani-
mals (National Research Council).
Genomic DNA preparation
Following euthanasia, duplicate samples of genomic DNA
were prepared from large segments of the tail from each of
the 4,000 mice. For each DNA sample, approximately 4
cm of the tail, cut into two pieces, was placed into a Serum
Separation Tube (Becton Dickinson Vacutainer SST tube,
13 × 100 mm, Fisher, Pittsburgh, PA). Each tail sample
was covered with 1.5 ml of tail lysis buffer (10 mM Tris-
HCl, pH 7.6, 10 mM EDTA, 100 mM NaCl, 0.5% SDS, 0.1
mg/ml Proteinase K), covered with parafilm and incu-
bated overnight at 50°C. After incubation, 1.5 ml of buff-
ered phenol (500 g of JT Baker crystal phenol, 100 ml of
2M Tris pH 8.0, 130 ml of double-distilled water, 25 ml of
m-cresol, 1 ml of 2-mercaptoethanol and 0.5 g of 8-
hydroxyquinoline) were added to each SST tube and the
samples were mixed thoroughly in a rack vortexer. Tubes
were placed in a Beckman Model TJ-6 tabletop centrifuge
and spun at full speed (2800–3000 rpm) for 20 minutes.
Following centrifugation, the DNA was extracted twice
with chloroform; 1.5 ml of chloroform were added to
each tube, vortexed, centrifuged at full speed for 20 min-
utes, and repeated. The DNA solution on top of the gel
barrier was transferred to a 13-ml Sarstedt tube (Sarstedt,
Newton, NC), and DNA was precipitated by addition of
two volumes of 95% EtOH. The precipitated DNA was
transferred to a 1.5 ml microcentrifuge tube with a sterile
pipette tip, air dried for 10 min to evaporate the ethanol,
resuspended in 400 µl of TE (10 mM Tris, 1 mM EDTA, pH
8.0), and stored at 4°C. In preparation for PCR and TGCE
screening, the concentrations of the DNA samples were
determined with a spectrophotometer. On average, each
sample yielded a total of approximately 500 µg of
genomic DNA.
Tissue cryopreservation
The brain, heart, spleen, lungs, kidneys, testes, and por-
tions of the liver and small intestine were harvested from
each of the 4,000 G1 mice, snap frozen in liquid nitrogen,
pooled together into a 50 ml polypropylene tube (BD Fal-
con BlueMax) on dry ice, and ground into a coarse powder
in liquid nitrogen with a mortar and pestle. The tissue
powder from each mouse was distributed into four 2-ml
Nunc cryotubes on dry ice and then stored in two liquid-
nitrogen freezers.
Sperm cryopreservation
Sperm cryoprotectant consisted of 18.0% D-(+)-Raffinose
pentahydrate (Sigma-Aldrich R7630) and 3.0% Dehy-
drated Skim Milk (Difco/BD 0032-17-3) in sterile water
(Sigma-Aldrich W1503). Water was warmed to approxi-
mately 40°C and raffinose was added with stirring until
completely dissolved. Skim Milk was added with contin-
ued stirring until dissolved. The solution was centrifuged
at 10,000 × g, 20°C, for 20 min. The supernatant was fil-
tered through a 0.45-micron filter, aliquoted, and stored
at -20°C. Individual aliquots were warmed on the day of
use to ensure that the raffinose and skim milk were in
solution.
For each of the 4,000 G1 males (≥ 12 weeks old), the epidi-
dymides and vas deferentia were removed and placed in 1
ml of sperm cryoprotectant in a small petri dish at 37°C.
Sperm was stripped from the vas deferentia into the cryo-
protectant by holding one end with a pair of forceps and
gently running another pair of forceps along the length of
the vas. The empty vas deferentia were discarded. The
epididymides were minced in the cryoprotectant with twoBMC Genomics 2005, 6:164 http://www.biomedcentral.com/1471-2164/6/164
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pair of forceps. After the dish remained undisturbed at
37°C for 2–3 minutes to allow the sperm to "swim out",
the pieces of tissue were removed with forceps and 100 µl
samples of sperm in cryoprotectant were drawn into 10
cryostraws (0.25 ml capacity, #A201; IMV, L'Aigle,
France), which were heat sealed on the ends. The sperm
samples were frozen in liquid nitrogen vapor for 10 min-
utes, followed by plunging the straws into liquid nitrogen
in two Dewar flasks for storage.
Preparation of RNA and first-strand cDNA templates from 
tissue powders
One of the four tubes of tissue powder (~0.5–1.0 g) from
each mouse was used to prepare total RNA using the RNe-
asy Maxi kit (Qiagen, Valencia, CA). The manufacturer's
protocol was used with the following modifications to
improve purity and yield of RNA. The tissue powder was
homogenized in the lysis buffer for 45–60 sec using a Pol-
ytron rotor-stator homogenizer, and 50% ethanol was
added to the homogenized lysate rather than 70% etha-
nol. After the second wash step, the RNeasy columns were
centrifuged an additional 5 min with the lids off to
remove residual traces of ethanol. The RNA was eluted
from the column by adding 0.8 ml of RNase-free water
that was preheated to 50°C, incubated for 5 minutes, cen-
trifuged, and then repeated with another 0.8 ml of water.
The eluted RNA was divided into two 1.5-ml tubes and
stored at -80°C. With this method, 1.5–3.5 mg of total
RNA was purified from each tube of tissue powder from
the first 736 CMMB mice (~18% of the entire bank).
First-strand cDNA templates were prepared as follows: 6
µg of total RNA, 0.9 µg of Random Hexamers (Amersham
Biosciences, Piscataway, NJ) or Random Primers (Invitro-
gen, Carlsbad, CA), 0.5 µg of Oligo(dT)12–18 (Invitrogen),
and RNase-free water, in a total volume of 40.5 µl, were
incubated at 65°C for 4 min and then immediately placed
on ice. A 60 µl cDNA-synthesis reaction was completed by
adding 12 µl of 5× First strand buffer [250 mM Tris-HCl
(pH 8.3), 375 mM KCl, 15 mM MgCl2] (Invitrogen), 3 µl
of 0.1 M DTT, and 3 µl of a 40 mM mixture of dNTPs (10
mM of each dNTP), and 1.5 µl (300 U) of Superscript III
reverse transcriptase (Invitrogen). The reaction was incu-
bated at 25°C for 10 min, followed by 50°C for 50 min,
and finally 70°C for 15 min.
PCR amplification of DNA and cDNA templates
For each of the 4,000 CMMB DNAs, 1 ml dilutions at 5
ng/µl were prepared. Aliquots of each diluted DNA (2 µl)
were transferred into 96-well master plates (AB-0600,
ABgene, Rochester, NY) and served as the templates for
mutation screening. The DNAs were arrayed into forty-
four 96-well plates, with 92 DNAs in each plate except for
the last plate, which contained 44 DNAs. The 736 first-
strand cDNAs were arrayed into eight 96-well plates (0.8
µl of first-strand cDNA reaction per well), with 92 cDNAs
in each plate. Well number 93 (row H, column 9) in the
DNA and cDNA plates contained unmutagenized C57BL/
6J DNA (negative control). Well number 94 (H10) con-
tained DNA from a C57BL/6J mouse with a known ENU-
induced heterozygous point mutation (positive control
for PCR and TGCE). Replica plates were made in batches
of 10 for every DNA and cDNA plate. The plates were
incubated at 70°C for 10–15 min to dry down the sam-
ples, sealed with TR100 adhesive seals for microtiter
plates (Marsh, Rochester, NY), and stored at -20°C until
ready for use in PCR or RT-PCR.
PCR primers (19–24 nt), designed to produce amplicons
~150–600 bp in length, were selected using Mac Vector
(Accelrys, San Diego, CA), Primer3 [47], or by visual
examination of the DNA or cDNA sequence. Primer
sequences were examined by BLAST analysis [48] against
the mouse genome in order to select unique primer pairs.
The DNA sequences of the primer pairs used for PCR
amplification of the amplicons listed in Table 1 are shown
in Table 3. The optimal PCR conditions for each pair of
primers (or multiplexed pairs of primers) were deter-
mined with wild-type C57BL/6J DNA or cDNA in a gradi-
ent thermal cycler (Eppendorf Gradient Mastercycler).
When screening the cDNA archive by multiplexed PCR,
primer dilution was used to generate approximately equal
amounts of RT-PCR products from target genes with dif-
ferent levels of expression.
To perform the PCR reactions with genomic DNA tem-
plates, master mixes were made for each amplicon (or
multiplexed amplicons) and 10 µl of the mix were added
to wells 1–93, which contained the following compo-
nents: 10 ng dried DNA template, 1× PCR buffer (20 mM
Tris-HC1, pH 8.0, 500 mM KCl; Invitrogen), 40 ng of each
primer (Sigma-Genosys, The Woodlands, TX), 1.5 mM
MgCl2, 0.4 mM dNTPs (Invitrogen) and 0.5 U of Platinum
Taq DNA polymerase (Invitrogen). To perform the PCR
reactions with cDNA templates, master mixes were made
for each amplicon (or multiplexed amplicons) and 20 µl
of the mix was added to wells 1–93, which contained the
following components: 0.8 µl dried cDNA template, 1×
PCR buffer (same as for DNA templates), 1.75 mM MgCl2,
0.2 mM of each dNTP, 0.2 mM of each primer (Integrated
DNA Technologies, Coralville, IA), and 0.1 µl (1 U) of
Platinum Taq DNA polymerase (Invitrogen). Master mix
with primers specific for the known ENU-induced muta-
tion was added to the dried template in well 94 of each
plate. PCR amplification was conducted in either Peltier
Thermal Cycler-200 units (MJ Research/Bio-Rad Labora-
tories, Waltham, MA), a DNA Engine Tetrad 2 (MJ
Research/Bio-Rad Laboratories), or Eppendorf Mastercy-
cler units (Brinkmann/Eppendorf, Westbury, NY). The
standard cycling conditions used were as follows (with theBMC Genomics 2005, 6:164 http://www.biomedcentral.com/1471-2164/6/164
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annealing temperature and sometimes the number of
cycles varying with certain amplicons): an initial 94°C
incubation for 3 min; followed by 30 cycles of 94°C for
30 sec, 60°C annealing for 30 sec, and 72°C for 45 sec;
and a final incubation at 72°C for 7 min. After comple-
tion of PCR, the reactions were denatured and reannealed
to allow the formation of any heteroduplexes and the
plates were stored at -20°C until they were screened by
TGCE for the presence of heteroduplexes.
Mutation screening PCR amplicons by TGCE with the 
SCE9612
Prior to TGCE analysis of the PCR products, additional
positive-control samples (for TGCE) were added to wells
95 (H11) and 96 (H12) of each plate. Well 95 contained
DNA for the same known ENU-induced mutation as well
94. However, the difference for well 95 is that PCR of the
DNA and heteroduplex formation of the PCR product
were previously performed in bulk, and an aliquot of the
sample was previously shown to display the mutation
(heteroduplex) by TGCE analysis. Well 96 contained DNA
from a second known ENU-induced mutation in which
PCR and heteroduplex formation were also previously
performed in bulk.
Heteroduplexed PCR products were analyzed by TGCE in
the SpectruMedix (State College, PA) SCE9612 Reveal
Mutation Detection System. The TGCE reactions were typ-
Table 3: PCR primer sequences used to amplify DNA (D) or cDNA (C) templates for mutation screening. The order of the amplicons 
listed is the same as in Table 1.
Gene symbol Amplicon size (bp) Template Forward primer (5' to 3') Reverse primer (5' to 3')
Mc1r 579 D gaggatccttcctgacaagactatgtcca aacggctgtgtgcttgtagtagg
Mc1r 446 D tcgtctccagcaccctctttatc gagtcgacgatcaccaggagcacagcagca
Mc1r 527 D gcacacttctaatggagagtg ggctcaggtagagacatgcc
Zfp111 352 D ccagagagaaataatgcccc caagaaccctgggctctcc
Zfp111 327 D ggttcagtcaggtctcacac caggattgatataatgctcc
Scnm1 394 D aggcacagcgtctcaaagtattgt atagggtagtaggggtcaccactc
Scnm1 484 D ggcaagaagcatttgtccagtaag tttctcagaatacaatctggagagc
Scnm1 372 D tgagttcccgtcagccaggacttc ctcactcaccttcggagggtaagg
Usp29 300 D ccttactcatcgacaagttatc tggaggaggatggttctgtctt
Usp29 336 D gggtctgctggcaccaaaaggt ggcaacaagtcagtggtaact
Usp29 298 D gggtcttcaagaggttccagag gagcctgtaattctgaagatca
Zim1 298 D ggaagaagacaggggataattcc ggagcgctctgtggtgttgtag
Zim1 298 D atcttcgggtcaaacatcagca gtagtgtgtgaggaagtatgaga
Zim1 302 D tggagagtgtaacaagtgcttc ggtgcttgagaagggctactttg
Zim1 302 D cccggagtgtgggaaagtcttc ggtgaatcagcagggtagccagt
Myd88 429 D ggctggcaggagacttaagg caggaagcacgtttcctcac
Myd88 196 D cacccttctcttctccacag gcccacctattctacctagg
Myd88 497 D ccttctgcagaggctgattg ccaaagcaggcctaagcttac
Myd88 245 D cgtggtcctaataccacacc ggaggcaagcggaagaacac
Ap2s1 424 D gccttgtctgtacctgtctc ggacgagcaggcaggttggtc
Capsl 372 D gaggtaaacctagggcttctg ctgccacgctgtcaataccg
Capsl 344 D gcacatgcatttctccatgg gctttgtaaggctctgaacc
Antxr1 419 D gagaatgggagatgaagttgg gttcacctagcactttgtgg
Antxr1 335 D catatggctgtcaacagcaagg gagtgtcggttaaggagaag
Antxr1 157 D gacgatctccaaagattcgg gtaggactctgtggctgatg
Antxr1 363 C gttctgccaggaggagacac gcagatggtggatggttcag
Antxr1 490 C aggctctccaaggcattatcc ccatcatcgtcttcttcctcac
Antxr1 489 C gctgctctggtggttctg gtgttgttcaggggatacttg
Ap2a1 510 C agaacgctatcctctttgagacc ggacgtcatcacggttgg
Ap2a1 543 C ggcttttgctgcagacattc aggttgggctcactgtcatag
Ap2a1 442 C gttgtcggtgcgcttcc catataccagggcaagtccag
Ap2a1 531 C ctatgtgagcgaggaggtgtgg cggctgtcatctagggcactg
Ap2a1 351 C agcgggagtcgtccatcttg gagctgggtcagccaacaaag
Pak4 503 C aacacatacccacgggctgac cgcatgatcaccacctcattg
Pak4 477 C gtacgcgggcacagagttc ccgacatgttctcaaattcgtc
Pak4 459 C aggatggggctctcactctg cattaggggccatggtatgtg
Pak4 412 C caagcagcaaagacgtgaaactg atagggaaggcgggagatgag
Pak4 447 C ctgtccgacttcgggttttgtg gtagccaggctctttggttcaagacBMC Genomics 2005, 6:164 http://www.biomedcentral.com/1471-2164/6/164
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ically conducted using a single 50–60°C temperature gra-
dient, 5-Kv injection voltage, and 30-sec injection time.
Adjustments in the injection voltage and injection time
were occasionally necessary for screening the cDNA tem-
plates due to the variability in the amount of RT-PCR
products in multiplexed reactions, which is inherent in
the differences in the expression levels for different genes.
Moreover, in some instances, dilutions (1:20–1:40) of RT-
PCR products were also required for optimal TGCE analy-
sis of cDNA templates amplified from genes that are
highly expressed.
Separations of heteroduplexes from homoduplexes were
achieved with the Reveal high-resolution matrix (Spectru-
Medix MREV-HR-225-001v3). The DNA fragments in 1×
running buffer (diluted 5× buffer; SpectruMedix BRUR-
500-003) were detected in the SCE9612 by measuring
laser-induced fluorescence of the ethidium bromide-
stained DNA. Raw-image data files were generated by the
SpectruMedix Checkmate software, and subsequently
processed by Revelation 2.4 mutation analysis software
that produced baseline-corrected single-color traces for
every capillary and automatically compared electrophero-
grams from experimental and control samples. Identifica-
tion of samples containing heteroduplexes was performed
by both Revelation 2.4 software analysis and visual
inspection of the electropherograms.
DNA sequence analysis
Direct DNA sequencing of the PCR-amplified gene frag-
ments was performed: (1) on amplicons from CMMB
samples yielding heteroduplexes (as identified by TGCE
analysis) in order to identify the ENU-induced point
mutation; (2) on amplicons from sperm DNA of CMMB
mice prior to ICSI; (3) and on DNA from tail biopsies or
ear punches of mice recovered by ICSI for genotyping.
Genomic DNA was extracted from sperm with the Hot-
SHOT method [49] using 5–10 µ1 of the same sperm sam-
ple (in NIM and 8% PVP, see below) that was used for
ICSI. Typical PCR reactions included: 1× PCR buffer, 2.27
mM MgCl2, 0.52 mM dNTPs, 260 ng of each primer, 40 ng
of DNA template, and 5 units of Platinum Taq  DNA
polymerase (Invitrogen) in a total reaction volume of 100
µl. Typical PCR conditions were: 94°C for 5 min; 29 cycles
of 94°C for 30 sec, the optimal annealing temperature for
each primer pair for 45 sec, 72°C for 30 sec; 72°C for 2
min; and 4°C hold. The PCR products were purified with
the QIAquick PCR Purification Kit (Qiagen) and DNA was
eluted from the columns with 30 µl of elution buffer. The
purified DNA and primers were submitted to the DNA
sequencing core at the University of Tennessee, Knoxville,
where DNA was labeled and fluorescent automated DNA
sequencing was performed on an ABI PRISM 3100
Genetic Analyzer (Applied Biosystems, Foster City, CA)
according to standard protocols.
Mice used for ICSI
Mice were obtained at 5 weeks of age from the following
sources: B6D2F1 (C57BL/6 × DBA/2) from Taconic (Ger-
mantown, NY) and Harlan (Indianapolis, IN), and
C57BL/6J from The Jackson Laboratory (Bar Harbor, ME).
The mice were fed ad libitum with a standard diet and
maintained in a temperature and light-controlled room
(22°C, 14L:10D) in ventilated caging and racks (Thoren,
Hazleton, PA) with automated watering (Edstrom Indus-
tries, Waterford, WI) in a specific-pathogen free (SPF)
environment.
Oocyte collection for ICSI
Mice (7–12 weeks of age) were superovulated with IP
injections of 5 IU PMS (Calbiochem, San Diego, CA) and
5 IU HCG (Sigma-Aldrich) given 48 hours apart. Oviducts
were removed 15 hours (B6D2F1) or 12 hours (C57BL/
6J) after HCG injection and placed in PBS in a petri dish.
The cumulus-oocyte mass was released from the ampulla
of the oviduct by rupturing the oviduct with a pair of tis-
sue forceps into 0.1% bovine testicular hyaluronidase
(Sigma-Aldrich) in M2 medium (Specialty Media, Phil-
lipsburg, NJ) to disperse the cumulus cells. The oviduct
was discarded and the oocytes collected and washed 3× in
M2 medium and placed in Fertilization Medium (Cooper
Surgical, Trumbull, CT) in a 37°C incubator with 5% CO2
in air and allowed to "rest" for 1 hour before ICSI.
Sperm preparation for ICSI
One straw containing the sperm from a mouse in the
CMMB with the desired ENU-induced mutation was
removed from liquid nitrogen and thawed immediately in
a 37°C water bath. The straw was sprayed with 70% etha-
nol and aseptically cut on both ends and the contents col-
lected in a 1.5 ml microcentrifuge tube. After
centrifugation for 10–15 seconds at high speed, the pel-
leted sperm were then washed in 1 ml NIM medium
(nucleus isolation medium; 125 mM KCl, 2.6 mM NaCl,
7.8 mM NaH2PO4, 1.4 mM KH2PO4, 3.0 mM EDTA diso-
dium salt in ultrapure water, pH adjusted to 7.2, filtered
and autoclaved) and centrifuged again for a few seconds.
The sperm pellet was then resuspended in 300 µl of NIM
medium, pipeted vigorously (to aid in removing the tails
from the sperm heads), and 15 µl aliquots were distrib-
uted into cryovials and refrozen by placing and storing the
vials in the vapor phase of liquid nitrogen in a liquid
nitrogen freezer. One aliquot was used for ICSI per day.
ICSI procedure
ICSI was carried out essentially as described by Kimura
and Yanagimachi [35] with a few modifications. Injection
needles (ID 6 mm, 25° bevel) were purchased from Hum-
agen (Charlottesville, VA). Holding pipets (25° bevel)
were purchased from Eppendorf (Westbury, NY). A 15 µl
aliquot of the sperm sample in NIM medium was mixedBMC Genomics 2005, 6:164 http://www.biomedcentral.com/1471-2164/6/164
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1:1 with NIM medium containing 16% polyvinyl pyrro-
lidone (PVP, Mr 360 kDa), resulting in sperm in NIM with
8% PVP for ICSI. Two 7 µl drops of the sperm sample were
placed on the injection plate (the cover of a plastic 100
mm Optilux petri dish, BD Falcon, No. 351005), together
with two 7 µl drops of NIM with 8% PVP (to condition the
injection needle) and two 7 µl drops of M2 medium
(where oocytes were placed and ICSI occurred), which
were all overlaid with Mineral Oil containing Vitamin E
(Walgreens, Oak Ridge, TN). ICSI was performed using
Eppendorf Micromanipulators (TransferMan NK2) with a
piezo-electric actuator (Piezo Impact Micro-Manipulator,
PMM-150FU System; PrimeTech, Ibaraki, Japan). A single
sperm head (without the tail) was collected and injected
immediately into an oocyte. The speed and intensity set-
tings on the PMM operation box (OP-15) for zona coring
were 5–6 and 5, respectively. The speed and intensity of
oolema penetration were both 1–2. ICSI was performed
1–4 hours after oocyte collection. Sperm-injected oocytes
were transferred into another dish of M2 Medium at room
temperature to allow them to "rest" for approximately 20
min before being transferred into pre-equilibrated Cleav-
age Medium (Cooper Surgical) for several hours at 37°C,
5% CO2. Cleavage Medium was changed every hour prior
to overnight culture.
Preimplantation culture of injected ova
Following ICSI, the injected ova were cultured overnight
to the 2-cell stage. Groups of 15–20 oocytes were trans-
ferred from Cleavage Medium to 25-µl drops of KSOM
Medium (Specialty Media) that were overlaid with
Embryo Tested Mineral Oil (Sigma-Aldrich) and pre-
equilibrated at 37°C and 5% CO2 in 60 mm plastic cul-
ture dishes (BD Falcon, No. 353002).
Embryo transfer
After overnight culture, the 2-cell embryos were trans-
ferred into the oviducts of pseudopregnant ICR (Harlan)
and B6D2F1 mice. The females were naturally mated to
vasectomized ICR males. Following analgesia (Buprenex)
and anesthesia (Avertin), the oviducts of pseudopregnant
females were exposed through a small incision in the skin
and body wall. The embryos (15–40) were transferred
unilaterally into one ampulla with a glass capillary
through a small opening in the oviduct between the ovary
and ampulla made with the tip of a 30-gauge needle. The
body wall was closed with a sterile absorbable suture and
the skin was closed with a wound clip. Mice were permit-
ted to recover from surgery in a pre-warmed cage.
Genotyping mutant mice rederived by ICSI
The wild-type and heterozygous mutant G2 mice recov-
ered by ICSI were genotyped by the same PCR and TGCE
strategy (described above) originally used to identify the
mutation in the DNA samples. The homozygous wild-
type, heterozygous, and homozygous mutant offspring
produced from the intercrosses of heterozygous mutant
mice were genotyped either by TGCE or DNA sequencing
of PCR products. For large numbers of mice, TGCE was
used to identify heterozygous mice from homozygous
mice. Since TGCE cannot distinguish between
homozygous mutant and homozygous wild-type mice,
the PCR products from all homozygous mice were then
mixed with an equal volume of PCR product from a wild-
type C57BL/6J control mouse and the TGCE was repeated,
which then resulted in the identification of homozygous
mutants (heteroduplexes detected) from homozygous
wild-types (no heteroduplexes detected). Alternatively,
smaller numbers of mice were genotyped by direct DNA
sequencing of PCR products, as described above.
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